Leptospermone is a defining beta-triketone of manuka oil and one of the better-studied isolated constituents in the AromaForge archive. The current source-grounded evidence is strongest for identity, repeated occurrence in manuka oil, plant HPPD inhibition, and several direct preclinical studies spanning virucidal, scabicidal, and insecticidal models. That research is materially stronger than for many niche aroma constituents, but it remains laboratory and agricultural or veterinary-stage evidence rather than human clinical validation. AromaForge should therefore describe leptospermone as a major manuka chemistry marker with notable preclinical mechanism data, while avoiding medical claims.
Chemical identity and composition
PubChem lists leptospermone as CID 3083632 with formula C15H22O4 and IUPAC name 2,2,4,4-tetramethyl-6-(3-methylbutanoyl)cyclohexane-1,3,5-trione. In the archive's current manuka record, leptospermone is the dominant named constituent at 11.15% in one 2025 GC/MS report, and a 2025 scabies paper quantified leptospermone at 17.2% in a tested manuka oil sample. This makes leptospermone a core identity marker for triketone-rich manuka chemotypes.
Aroma and practical use
- Use the recorded manuka-like, medicinal, herbaceous, warm descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2005 cell-culture study found that leptospermone inhibited HSV-1 virulence; when the virus was pretreated before infection, plaque formation was reduced by 79.7% at non-cytotoxic concentrations.
A 2005 cell-culture study found that leptospermone inhibited HSV-1 virulence; when the virus was pretreated before infection, plaque formation was reduced by 79.7% at non-cytotoxic concentrations.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2007 study identified plant HPPD as a herbicidal target site for manuka beta-triketones and reported an apparent I50 of 3.14 microg/mL for leptospermone against HPPD, with competitive reversible inhibition.
A 2007 study identified plant HPPD as a herbicidal target site for manuka beta-triketones and reported an apparent I50 of 3.14 microg/mL for leptospermone against HPPD, with competitive reversible inhibition.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2013 mechanistic paper reported that absorbed leptospermone was readily taken up by roots, that about 50% of absorbed material was translocated to foliage, and that its plant behavior was consistent with its physico-chemical properties.
A 2013 mechanistic paper reported that absorbed leptospermone was readily taken up by roots, that about 50% of absorbed material was translocated to foliage, and that its plant behavior was consistent with its physico-chemical properties.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2025 scabies paper reported that leptospermone had strong miticidal and ovicidal activity against scabies mites and was the most potent of the tested beta-triketones in egg assays, while docking and metabolite results supported HPPD-linked interference in the parasite.
A 2025 scabies paper reported that leptospermone had strong miticidal and ovicidal activity against scabies mites and was the most potent of the tested beta-triketones in egg assays, while docking and metabolite results supported HPPD-linked interference in the parasite.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025 mosquito toxicology paper reported rapid knockdown and toxicity of leptospermone to Aedes aegypti with topical and tarsal LD50 values of 150 ng/mg mosquito and 357 ng/cm2, and linked this effect to mosquito carbonic anhydrase inhibition rather than HPPD inhibition.
A 2025 mosquito toxicology paper reported rapid knockdown and toxicity of leptospermone to Aedes aegypti with topical and tarsal LD50 values of 150 ng/mg mosquito and 357 ng/cm2, and linked this effect to mosquito carbonic anhydrase inhibition rather than HPPD inhibition.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Within the archive's current manuka record, leptospermone was directly quantified at 11.15% in a 2025 GC/MS report, confirming it as a major batch constituent rather than only a literature-reported marker.
Within the archive's current manuka record, leptospermone was directly quantified at 11.15% in a 2025 GC/MS report, confirming it as a major batch constituent rather than only a literature-reported marker.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific human clinical safety trial, IFRA restriction, or dermal maximum for isolated leptospermone was verified in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the strongest leptospermone data come from plant, viral, mite, and insect models, archive copy should avoid implying proven therapeutic or antiparasitic effects in people.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
IsoleptospermoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Isoleptospermone report →FlavesoneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Flavesone report →How the effects were investigated
hppd inhibition in plants
Leptospermone is a natural beta-triketone that inhibits plant p-hydroxyphenylpyruvate dioxygenase, producing the characteristic bleaching phenotype associated with HPPD-targeting herbicides.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
direct virucidal contact effect
In HSV cell-culture work, leptospermone reduced plaque formation when virus particles were pretreated before host-cell infection, supporting a direct virion-level effect in that assay system.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
possible hppd link in scabies model
A 2025 scabies study linked manuka beta-triketone activity to probable interference with mite tyrosine catabolism and HPPD, but that conclusion remains an in vitro plus in silico model rather than confirmed in vivo parasite pharmacology.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
carbonic anhydrase inhibition in mosquitoes
A 2025 Aedes aegypti paper reported that leptospermone toxicity in mosquitoes was associated with mosquito carbonic anhydrase inhibition rather than plant-style HPPD inhibition, indicating target behavior depends on the biological system.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical evidence for isolated leptospermone was verified in this pass.
- The mechanistic story is system-dependent, with plant HPPD inhibition established but mosquito toxicity linked instead to carbonic anhydrase inhibition.
- No IFRA standard, Tisserand & Young dermal maximum, or peer-reviewed dermal-limit/phototoxicity/sensitization study specific to isolated leptospermone was located in this pass; Tisserand & Young's 'no contraindications' note applies to whole manuka oil, not the isolated beta-triketone, so dermal_limit_pct was reset to null rather than treated as verified.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.